JP2004501605A - Ｈｅｒ−２に結合するアンタゴニスト - Google Patents

Ｈｅｒ−２に結合するアンタゴニスト Download PDF

Info

Publication number
JP2004501605A
JP2004501605A JP2001560693A JP2001560693A JP2004501605A JP 2004501605 A JP2004501605 A JP 2004501605A JP 2001560693 A JP2001560693 A JP 2001560693A JP 2001560693 A JP2001560693 A JP 2001560693A JP 2004501605 A JP2004501605 A JP 2004501605A
Authority
JP
Japan
Prior art keywords
seq
sequence
ecd
amino acids
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001560693A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004501605A5 (https=
Inventor
クリントン　ゲイル
ヘンナー　ウィリアム　ディー
エヴァンス　アダム
Original Assignee
オレゴン　ヘルス　サイエンセズ　ユニヴァーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オレゴン　ヘルス　サイエンセズ　ユニヴァーシティー filed Critical オレゴン　ヘルス　サイエンセズ　ユニヴァーシティー
Publication of JP2004501605A publication Critical patent/JP2004501605A/ja
Publication of JP2004501605A5 publication Critical patent/JP2004501605A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2001560693A 2000-02-16 2001-02-16 Ｈｅｒ−２に結合するアンタゴニスト Pending JP2004501605A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/506,079 US7625859B1 (en) 2000-02-16 2000-02-16 HER-2 binding antagonists
PCT/US2001/005327 WO2001061356A1 (en) 2000-02-16 2001-02-16 Her-2 binding antagonists

Publications (2)

Publication Number Publication Date
JP2004501605A true JP2004501605A (ja) 2004-01-22
JP2004501605A5 JP2004501605A5 (https=) 2006-06-22

Family

ID=24013084

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001560693A Pending JP2004501605A (ja) 2000-02-16 2001-02-16 Ｈｅｒ−２に結合するアンタゴニスト

Country Status (7)

Country Link
US (4) US7625859B1 (https=)
EP (1) EP1257822B1 (https=)
JP (1) JP2004501605A (https=)
AT (1) ATE542138T1 (https=)
AU (1) AU4157501A (https=)
CA (1) CA2400473A1 (https=)
WO (1) WO2001061356A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017518038A (ja) * 2015-01-30 2017-07-06 ジェノー バイオファーマ カンパニー リミテッド 抗ｈｅｒ２完全ヒト抗体の突然変異体抗体、及びそれをコードする遺伝子並びにそれらの使用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
AU779612C (en) 1999-07-02 2005-12-15 Genentech Inc. Peptide compounds that bind HER2
JP2006524035A (ja) * 2002-12-26 2006-10-26 シーマインズ リミテッド ライアビリティ カンパニー 癌の診断、予後診断および治療のための方法および組成物
EP1601684B1 (en) * 2003-03-05 2014-10-15 Dendreon Corporation Alternative reading frame polypeptides for treatment
TWI472339B (zh) * 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
NZ596468A (en) * 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
US9427458B2 (en) 2010-07-22 2016-08-30 Consejo Nacional De Investigaciones Cientificas Y Tecnicas, Conicet Methods for inhibiting cancer cell proliferation
KR101258144B1 (ko) 2011-07-22 2013-04-30 한양대학교 산학협력단 Ｅｃｍ１ 항체를 함유하는 항암용 조성물
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
WO2023168426A1 (en) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
WO2024186690A2 (en) 2023-03-03 2024-09-12 Enosi Therapeutics Corporation Oligo-trap fusion proteins (ofps) and uses thereof

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633169A (en) * 1899-06-17 1899-09-19 Alexander Hazard Bottle-stopper.
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
EP0119528B1 (en) 1983-03-11 1992-05-13 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human renal cancer antigens and method
EP0171407B1 (en) 1984-01-30 1993-11-18 Imperial Cancer Research Technology Limited Improvements relating to growth factors
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US4933284A (en) * 1986-05-07 1990-06-12 Uop Regenerable dialkylaminoalkyl cellulose support matrix for immobilizing biologically active materials
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
CA1341191C (en) 1988-04-18 2001-02-27 Robert Allan Weinberg Detection of neu gene expression and products
EP0412118A4 (en) 1988-04-29 1991-09-25 Barry M. Fell Reinforced thermoplastic honeycomb structure
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US6207645B1 (en) * 1989-03-21 2001-03-27 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
CA2489769A1 (en) 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69031120T2 (de) 1989-05-19 1998-01-15 Genentech, Inc., South San Francisco, Calif. Her2 extrazellulare domäne
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
ES2166352T3 (es) 1989-08-04 2002-04-16 Schering Ag Dominio externo de c-erbb-2:gp75.
AU648261B2 (en) 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
WO1991005264A1 (en) 1989-09-29 1991-04-18 Oncogenetics Partners Detection and quantification of neu related proteins in the biological fluids of humans
US5149855A (en) * 1989-12-26 1992-09-22 Mitsubishi Rayon Co., Ltd. Process for racemizing optically active carboxylic acid esters
WO1991011715A1 (en) 1990-01-25 1991-08-08 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Detection of a characteristic antigen from carcinoma in body fluids
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
WO1991015230A1 (en) * 1990-04-06 1991-10-17 The Trustees Of The University Of Pennsylvania Ligand for the neu gene product
DE59104652D1 (de) 1990-05-10 1995-03-30 Ciba Geigy Ag Tinten.
US5874528A (en) 1990-05-25 1999-02-23 Georgetown University Binding peptides which interact with ligand growth factors of the epidermal growth factor receptor and erbB-2 receptor
US5578482A (en) 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
WO1992011033A1 (en) 1990-12-20 1992-07-09 Arch Development Corporation Control of gene expression by ionizing radiation
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE69232718T2 (de) 1991-02-22 2003-04-03 American Cyanamid Co., Madison Identifizierung eines menschlichen rezeptor-tyrosinkinasegens
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5580858A (en) * 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
US5674691A (en) 1991-06-21 1997-10-07 Amrad Corporation Limited Method of screening for ligands to a receptor-type tyrosine kinase
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
DE69228300T2 (de) 1991-08-22 1999-09-23 Becton Dickinson And Co., Franklin Lakes Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
EP0620826A1 (en) 1992-01-09 1994-10-26 Helsinki University Holding, Ltd. Tie, a novel endothelial cell receptor tyrosine kinase
US6331302B1 (en) 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
JPH07503372A (ja) 1992-01-23 1995-04-13 バイカル・インコーポレイテッド 生体外遺伝子導入
JPH05271294A (ja) * 1992-01-24 1993-10-19 Japan Found Cancer Res ヒトプロヒビチンおよびそれをコードするｄｎａ
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
JPH08508405A (ja) 1993-03-26 1996-09-10 トーマス ジェファーソン ユニバーシティ Ｉｇｆ−１レセプターアンチセンスオリゴヌクレオチドにより細胞の増殖を阻害し、且つ細胞を分化させる方法
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
PT695169E (pt) 1993-04-22 2003-04-30 Skyepharma Inc Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DK0814154T3 (da) 1993-09-15 2009-08-31 Novartis Vaccines & Diagnostic Rekombinante alfavirusvektorer
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
AU686277B2 (en) 1993-11-16 1998-02-05 Pacira Pharmaceuticals, Inc. Vesicles with controlled release of actives
US6696548B2 (en) 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US6045797A (en) 1994-03-14 2000-04-04 New York University Medical Center Treatment or diagnosis of diseases or conditions associated with a BLM domain
WO1995025166A1 (en) 1994-03-14 1995-09-21 New York University Medical Center Methods for treatment or diagnosis of diseases or conditions associated with abnormal signal transduction
WO1995030331A1 (en) 1994-05-05 1995-11-16 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
US5770567A (en) 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
IL115995A0 (en) 1994-11-15 1996-01-31 Bayer Ag Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5783404A (en) 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US5663144A (en) 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US6008373A (en) * 1995-06-07 1999-12-28 Carnegie Mellon University Fluorescent labeling complexes with large stokes shift formed by coupling together cyanine and other fluorochromes capable of resonance energy transfer
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6084085A (en) 1995-11-14 2000-07-04 Thomas Jefferson University Inducing resistance to tumor growth with soluble IGF-1 receptor
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
WO1997042338A1 (en) 1996-05-06 1997-11-13 Chiron Corporation Crossless retroviral vectors
CA2259157A1 (en) 1996-07-05 1998-01-15 Mount Sinai Hospital Corporation Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US5878712A (en) * 1996-09-20 1999-03-09 Fev Motorentechnik Gmbh & Co. Kg System for the direct injection of fuel in internal-combustion engines
ATE343400T1 (de) 1996-09-24 2006-11-15 Merck & Co Inc Verbindungen zur hemmung der angiogenese durch gentherapie
US5910583A (en) 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US7125969B1 (en) 1996-11-27 2006-10-24 The Regents Of The University Of California ETS-related gene overexpressed in human breast and epithelial cancers
US20020172965A1 (en) * 1996-12-13 2002-11-21 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1998058053A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. Human receptor tyrosine kinase, kdr
US5877171A (en) * 1997-07-28 1999-03-02 Mcleod; Malcolm N. Method of treating pre-menstrual syndrome using chromium
EP1023605A1 (en) 1997-10-15 2000-08-02 Abbott Laboratories Methods and compositions for detecting hepatitis e virus
DK1510579T3 (da) 1998-02-04 2009-11-30 Genentech Inc Anvendelse af heregulin som en epitelcellevækstfaktor
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
DK1308455T3 (da) 1998-05-06 2006-07-31 Genentech Inc Sammensætning omfattende anti-HER2-antistoffer
US20030092063A1 (en) 1998-05-15 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999064589A1 (en) 1998-06-11 1999-12-16 Astrazeneca Ab Human receptor tyrosine kinase
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
NZ511019A (en) 1998-11-07 2003-11-28 Genentech Inc An isolated ligand, which is a heregulin polypeptide, to activate HER2 and/or HER3 receptors to induce inner ear hair cell generation
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
WO2000035455A1 (en) 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
AU5003200A (en) 1999-05-14 2000-12-05 United States Of America As Represented By The Department Of Veterans Affairs, The Isolation and characterization of epidermal growth factor related protein
AU779612C (en) 1999-07-02 2005-12-15 Genentech Inc. Peptide compounds that bind HER2
EP1226441A4 (en) 1999-10-15 2003-08-06 Human Genome Sciences Inc POLYNUCLEOTIDES, POLYPEPTIDES AND ANTIBODIES OF THE PROTEIN-TYROSIN KINASE RECEPTOR
EP1245236A4 (en) * 1999-12-28 2004-09-22 Sumitomo Pharma PROPHYLACTICS AND THERAPEUTICS FOR TREATING CHRONIC HEPATITIS
CA2407556C (en) 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
TWI317285B (en) 2000-07-28 2009-11-21 Dainippon Sumitomo Pharma Co New use and kit for remedies for cancer
WO2002011677A2 (en) 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
WO2002012335A2 (en) 2000-08-10 2002-02-14 Pharmacia Corporation A NEW EGF MOTIF REPEAT PROTEIN OBTAINED FROM A cDNA LIBRARY FROM HS-5 STROMAL CELL LINE
US6818424B2 (en) * 2000-09-01 2004-11-16 E. I. Du Pont De Nemours And Company Production of cyclic terpenoids
US6686940B2 (en) * 2000-11-16 2004-02-03 Minolta Co., Ltd. Reversible image display medium
EP1228766A1 (en) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
US20020104642A1 (en) * 2001-02-05 2002-08-08 Garner Scott D. Heat pipe system for heat reduction in automobiles
US7213546B2 (en) * 2001-03-21 2007-05-08 Steven Vermeer Engine airflow management system
WO2002090991A2 (en) 2001-05-03 2002-11-14 Oxford Glycosciences (Uk) Ltd Proteins and genes for diagnosis and treatment of erbb2-related cancer
WO2002097114A2 (en) 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
US7125680B2 (en) 2001-07-27 2006-10-24 The Regents Of The University Of California Methods and materials for characterizing and modulating interaction between heregulin and HER3
EP2135960A1 (en) 2001-09-19 2009-12-23 Intergenetics Incorporated Genetic analysis for stratification of cancer risk by determining the allelic profile of the VDR-ApaI and CYP11B2 genes
WO2003035843A2 (en) 2001-10-25 2003-05-01 Buck Institute For Age Research Screening system for modulators of her2 mediated transcription and her2 modulators identifed thereby
US7200845B2 (en) * 2001-12-03 2007-04-03 Hewlett-Packard Development Company, L.P. System and method for high availability firmware load
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
EP1569689A4 (en) 2002-01-18 2009-08-05 Novartis Vaccines & Diagnostic IL2 / ANTI-HER2-ANTIBODY COMBINATION THERAPY AGAINST CANCER, which is characterized by overexpression of the HER2-RECEPTOR PROTEIN
EP2289942B1 (en) 2002-04-10 2013-07-31 Genentech, Inc. Anti-HER2 antibody variants
WO2004008099A2 (en) 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
WO2004041065A2 (en) 2002-10-30 2004-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR PROPHYLAXIS AND TREATMENT OF HER-2/neu TUMORS
EP1418527A1 (en) * 2002-11-08 2004-05-12 Motorola, Inc. Multiple SIM card holding apparatus
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
SE0203746D0 (sv) 2002-12-18 2002-12-18 Karolinska Innovations Ab New compounds
SE0203747D0 (sv) 2002-12-18 2002-12-18 Karolinska Innovations Ab New use
US7009714B2 (en) * 2003-02-26 2006-03-07 Hitachi High-Technologies Corporation Method of dry etching a sample and dry etching system
AU2004265226A1 (en) 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
CN100392074C (zh) 2003-10-15 2008-06-04 上海海欣生物技术有限公司 树突状细胞肿瘤疫苗及其制法和用途
EP1796711A2 (en) 2004-04-22 2007-06-20 Oregon Health and Science University Herstatin or intron 8-encoded domain thereof for modulating signaling mediated by igf-1 receptor and erbb receptors
CA2583230A1 (en) 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
US7251756B2 (en) * 2005-04-26 2007-07-31 International Business Machines Corporation Method and apparatus for increasing fuse programming yield through preferred use of duplicate data
US9394483B2 (en) * 2012-05-24 2016-07-19 Sabic Global Technologies B.V. Flame retardant polycarbonate compositions, methods of manufacture thereof and articles comprising the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017518038A (ja) * 2015-01-30 2017-07-06 ジェノー バイオファーマ カンパニー リミテッド 抗ｈｅｒ２完全ヒト抗体の突然変異体抗体、及びそれをコードする遺伝子並びにそれらの使用

Also Published As

Publication number Publication date
US20080219997A1 (en) 2008-09-11
US7935784B2 (en) 2011-05-03
ATE542138T1 (de) 2012-02-15
US7625859B1 (en) 2009-12-01
EP1257822B1 (en) 2012-01-18
AU4157501A (en) 2001-08-27
EP1257822A4 (en) 2004-09-08
WO2001061356A9 (en) 2002-10-31
US20100267027A1 (en) 2010-10-21
CA2400473A1 (en) 2001-08-23
WO2001061356A1 (en) 2001-08-23
EP1257822A1 (en) 2002-11-20
US20120045755A1 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
US20100267027A1 (en) Her-2 binding antagonists
US7396810B1 (en) Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7939080B2 (en) HER-2 binding antagonists
JP3989528B2 (ja) Ｄｎａ配列及びエンコードされた乳房に特異的な乳癌たんぱく質
US20070015907A1 (en) Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
US20090035819A1 (en) CA125 gene and its use for diagnostic and therapeutic interventions
AU2001286483A1 (en) Expression of herstatin, an alternative HER-2/NEU product, in cells that express either p185HER-2 or the EGF receptor inhibits receptor activity and cell growth
JP2002517185A (ja) 前立腺癌および結腸癌の診断および治療に有用な腫瘍抗原
EP1385879A1 (en) Reproductive cancer diagnosis and therapy
AU2002254800A1 (en) Reproductive cancer diagnosis and therapy
AU2001241575B2 (en) HER-2 binding antagonists
JP2004534525A (ja) ｕＰＡＲ変異体ｄｅｌ４、ｄｅｌ５およびｄｅｌ４＋５に対する単特異性のポリクローナル抗体の製法並びに診断および治療目的のためのその使用
AU2001241575A1 (en) HER-2 binding antagonists
US20090018071A1 (en) Epididymis-specific receptor protein
WO2004072285A1 (en) “goblin” cancer associated polypeptides, related reagents, and methods of use thereof
WO2014015028A1 (en) Methods for characterizing patients with colon cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090721